Yeast Particle Encapsulation of Scaffolded Terpene Compounds for Controlled Terpene Release by Soto, Ernesto R. et al.
University of Kentucky 
UKnowledge 
Maxwell H. Gluck Equine Research Center 
Faculty Publications Maxwell H. Gluck Equine Research Center 
5-27-2021 
Yeast Particle Encapsulation of Scaffolded Terpene Compounds 
for Controlled Terpene Release 
Ernesto R. Soto 
University of Massachusetts 
Florentina Rus 
University of Massachusetts 
Hanchen Li 
University of Massachusetts 
Carli Garceau 
University of Massachusetts 
Jeffrey Chicca 
University of Massachusetts 
See next page for additional authors 
Follow this and additional works at: https://uknowledge.uky.edu/gerc_facpub 
 Part of the Large or Food Animal and Equine Medicine Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Repository Citation 
Soto, Ernesto R.; Rus, Florentina; Li, Hanchen; Garceau, Carli; Chicca, Jeffrey; Elfawal, Mostafa; Gazzola, 
David; Nielsen, Martin K.; Urban, Joseph F. Jr.; Aroian, Raffi V.; and Ostroff, Gary R., "Yeast Particle 
Encapsulation of Scaffolded Terpene Compounds for Controlled Terpene Release" (2021). Maxwell H. 
Gluck Equine Research Center Faculty Publications. 58. 
https://uknowledge.uky.edu/gerc_facpub/58 
This Article is brought to you for free and open access by the Maxwell H. Gluck Equine Research Center at 
UKnowledge. It has been accepted for inclusion in Maxwell H. Gluck Equine Research Center Faculty Publications 
by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
Yeast Particle Encapsulation of Scaffolded Terpene Compounds for Controlled 
Terpene Release 
Digital Object Identifier (DOI) 
https://doi.org/10.3390/foods10061207 
Notes/Citation Information 
Published in Foods, v. 10, issue 6, 1207. 
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. 
This article is an open access article distributed under the terms and conditions of the Creative 
Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). 
Authors 
Ernesto R. Soto, Florentina Rus, Hanchen Li, Carli Garceau, Jeffrey Chicca, Mostafa Elfawal, David 
Gazzola, Martin K. Nielsen, Joseph F. Urban Jr., Raffi V. Aroian, and Gary R. Ostroff 
This article is available at UKnowledge: https://uknowledge.uky.edu/gerc_facpub/58 
foods
Article
Yeast Particle Encapsulation of Scaffolded Terpene Compounds
for Controlled Terpene Release
Ernesto R. Soto 1 , Florentina Rus 1, Hanchen Li 1, Carli Garceau 1, Jeffrey Chicca 1, Mostafa Elfawal 1,
David Gazzola 1, Martin K. Nielsen 2, Joseph F. Urban, Jr. 3,4 , Raffi V. Aroian 1 and Gary R. Ostroff 1,*


Citation: Soto, E.R.; Rus, F.; Li, H.;
Garceau, C.; Chicca, J.; Elfawal, M.;
Gazzola, D.; Nielsen, M.K.; Urban,
J.F., Jr.; Aroian, R.V.; et al. Yeast
Particle Encapsulation of Scaffolded
Terpene Compounds for Controlled
Terpene Release. Foods 2021, 10, 1207.
https://doi.org/10.3390/foods
10061207
Academic Editors: Ian Southwell
and Oscar Núñez
Received: 16 April 2021
Accepted: 20 May 2021
Published: 27 May 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA;
ernesto.soto-villatoro@umassmed.edu (E.R.S.); florentina.rus@umassmed.edu (F.R.);
hanchen.li@umassmed.edu (H.L.); carli.garceau@umassmed.edu (C.G.); jeffrey.chicca@umassmed.edu (J.C.);
mostafa.elfawal@umassmed.edu (M.E.); davidmgazzola@gmail.com (D.G.);
raffi.aroian@umassmed.edu (R.V.A.)
2 M.H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky,
Lexington, KY 40546, USA; martin.nielsen@uky.edu
3 Beltsville Human Nutrition Research Center, Diet, Genomics and Immunology Laboratory,
United States Department of Agriculture, Agricultural Research Service, Beltsville, MD 20705, USA;
joe.urban@usda.gov
4 Beltsville Agricultural Research Center, Animal and Parasitic Diseases Laboratory, United States Department
of Agriculture, Agricultural Research Service, Beltsville, MD 20705, USA
* Correspondence: gary.ostroff@umassmed.edu; Tel.:+1-508-856-1930
Abstract: Terpenes are naturally occurring compounds produced by plants that are of great com-
mercial interest in the food, agricultural, cosmetic, and pharmaceutical industries due to their broad
spectra of antibacterial, antifungal, anthelmintic, membrane permeation enhancement, and antioxi-
dant biological activities. Applications of terpenes are often limited by their volatility and the need
for surfactants or alcohols to produce stable, soluble (non-precipitated) products. Yeast particles (YPs)
are hollow, porous microspheres that have been used for the encapsulation of terpenes (YP terpenes)
by passive diffusion of terpenes through the porous YP cell walls. We here report the development of
a second generation YP encapsulated terpene technology that incorporates the stimuli-responsive
control of terpene release using biodegradable pro-terpene compounds (YP pro-terpenes). YP ter-
penes and YP pro-terpenes were both produced, in which high levels of carvacrol, eugenol, thymol
and geraniol were encapsulated. The YP pro-terpenes show higher encapsulation stability than YP
terpenes due to pro-terpenes being non-volatile solids at room temperature and stable in suspensions
at neutral pH. YP pro-terpenes and YP terpenes were evaluated for biological activity in antibacterial,
antifungal and anthelmintic assays. The YP pro-terpenes retained the full biological activity of the
parent terpene compound.
Keywords: terpenes; yeast particles; antimicrobial; anthelmintic; prodrug
1. Introduction
Terpenes are a large class of naturally occurring organic compounds that constitute
primary components of essential oils obtained from plants. The term terpene is commonly
used to include basic terpenes or hydrocarbons consisting of isoprene repeating units
and terpenoids or modified terpenes containing additional functional groups (usually
oxygen-containing groups). Terpenes have long been recognized for a wide range of func-
tional properties (e.g., anthelmintic, antifungal, antibacterial, and antioxidant properties).
Terpenes are used as excipients due to their permeation enhancer properties, or as bioactive
compounds in pharmaceutical products, as fragrances, permeation enhancers and antiox-
idants in cosmetics, for their broad range of potential applications against pathogens in
agricultural products, and can be used as additives in food packaging to prevent bacterial
spoilage and oxidation [1–3].
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The use of terpenes can present challenges primarily associated with (1) the chemical
instability of some isolated terpenes when exposed to air, heat, light and moisture; (2) poor
water solubility, and (3) high volatility. It is usually necessary to produce terpene-based
products containing high levels of surfactants or alcohols. Applications of terpenes in
certain products such as food preservatives poses challenges due to safety limits and
marked organoleptic effects. Encapsulation of terpenes in nano or microstructured systems
has been employed as a common approach to develop terpene formulations with improved
chemical stability, shelf-life, additionally opening up the possibility to control terpene
release [4–8].
We have developed methods using yeast particles (YPs) to efficiently encapsulate high
levels of terpenes. YPs are 3–5 µm hollow and porous microspheres, a byproduct of the food
grade Baker’s yeast (Saccharomyces cerevisae) extract manufacturing process. We have used
YPs for the encapsulation of a broad range of molecules for drug delivery and agricultural
applications [9–15]. Our first-generation approach to load terpenes inside the hydrophobic
cavity of YPs is based on passive diffusion of terpenes through the porous microsphere cell
walls without the need for surfactants or alcohols. Short-term sustained terpene release
from YPs is the reverse process and is a function of terpene water solubility. This approach
has been successfully implemented to develop and commercialize a YP-terpene based
fungicide and nematicide for agricultural applications [16–21]. More recently, we have
identified YP terpenes with broad-acting anthelmintic activity [22], which could lead to the
development of formulations for oral terpene delivery for the treatment of gastrointestinal
worm parasites and other infectious agents.
To develop better controlled terpene release, as well as to avoid limitations associated
with terpene volatility and stability, we have developed a second generation YP terpene
encapsulation approach using non-volatile, biodegradable pro-terpene compounds. The
pro-terpene compounds are (1) solids at room temperature with a high melting point
to avoid terpene loss due to the high volatility of terpenes, (2) water insoluble to avoid
premature release from aqueous-based YP compositions, (3) stable at neutral pH, and
(4) susceptible to chemical (pH) or enzymatic hydrolysis of a biodegradable linker provid-
ing for controlled release. This approach was first demonstrated for the YP encapsulation
of a pro-carvacrol compound [23]. The YP pro-carvacrol was shown to have similar in vitro
antibacterial properties as YP carvacrol, but with the additional benefits of improved
stability and controlled, sustained carvacrol release from YPs.
In this article, we report the use of the YP pro-terpene encapsulation approach of four
terpenes: carvacrol, eugenol, thymol, and geraniol and expanded testing against a wider
range of applications. The YP terpene and YP pro-terpene compositions were character-
ized for controlled terpene release and screened in vitro for antibacterial, antifungal, and
anthelmintic activity in model systems. The results show the potential broad range of
applications of YP terpenes and YP pro-terpenes, and the advantage of YP pro-terpene
encapsulation to improve the formulation stability and to control terpene release.
2. Materials and Methods
2.1. Materials
Yeast Particles (YPs) were purchased from Biorigin (Louisville, KY, USA). Terpenes
(carvacrol, eugenol, thymol, and geraniol) were procured from Penta Manufacturing
(Livingston, NJ, USA). All reagents and solvents for synthesis and HPLC analysis were
obtained from Fisher Scientific (Waltham, MA, USA) or Sigma Aldrich (St. Louis, MO,
USA). Lysogeny broth (LB) was purchased from Sigma Aldrich and yeast peptone dextrone
(YPD) was prepared from DifcoTM yeast extract, DifcoTM Bacto peptone and dextrose
(all materials obtained from Fisher Scientific) at a composition of 1% yeast extract, 2%
peptone and 2% dextrose. Reagents for worm culture medium were purchased from Gibco
(Gaithersburg, MO, USA).
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2.2. Methods
2.2.1. Synthesis of Pro-Terpene Compounds
Pro-terpenes were synthesized from the reaction of the parent terpene compound
and ethylenediaminetetracetic acid (EDTA) dianhydride based on a previously described
procedure for phenolic terpenes [23,24]. Briefly, terpene (18 mmol) and triethylamine (TEA,
64 mmol) were dissolved in 75 mL of anhydrous tetrahydrofuran (THF). EDTA dianhydride
(9 mmol) was added slowly to the THF solution. The reaction mixture was stirred under
nitrogen, at room temperature, overnight. The mixture was diluted in 500 mL of water and
concentrated HCl was added to immediately acidify to pH 2. The precipitated product was
filtered, washed with water, and dried under vacuum.
Pro-carvacrol–Yield: 71%; off-white powder; 1H-NMR (DMSO-d6, 500 MHz): δ ppm,
7.2 (d, 2H, Ar-H); 7.04 (d, 2H, Ar-H); 6.9 (s, 2H, Ar-H); 3.9 (s, 4H, CH2); 3.67 (s, 4H, CH2);
3.03 (s, 4H, CH2); 2.89 (m, 2H, CH); 2.05 (s, 6H, CH3); 1.1 (d, 12H, CH3)
Pro-eugenol–Yield: 81%; off-white powder; 1H NMR (DMSO-d6, 500 MHz): δ ppm,
6.9–7.0 (m, 4H, Ar-H); 6.7–6.8 (d, 2H, Ar-H); 6.0 (m, 2H, CH); 5.0–5.1 (m, 4H, CH2); 3.8 (s,
4H, CH2); 3.7 (s, 6H, CH3); 3.5 (s, 4H, CH2); 3.4 (d, 4H, CH2); 2.9 (s, 4H, CH2)
Pro-thymol–Yield: 60%; off-white powder; 1H NMR (DMSO-d6, 500 MHz): δ ppm, 7.2
(d, 2H, Ar-H), 7.05 (d, 2H, Ar-H); 6.85 (s, 2H, Ar-H); 3.9 (s, 4H, CH2); 3.6 (s, 4H, CH2); 2.9
(s, 4H, CH2); 2.8 (m, 2H, CH); 2.2 (s, 6H, CH3); 1.1 (d, 12 H, CH3)
Pro-geraniol–Yield: 27%; off-white powder; 1H NMR (DMSO-d6, 500 MHz): δ ppm,
5.35 (m, 2H, CH); 5.1 (m, 2H, CH); 4.6 (m, 4H, CH2); 3.95 (s, 4H, CH2); 3.6 (s, 4H, CH2); 3.1
(s, 4H, CH2); 2.0–2.1 (m, 8H, CH2); 1.65 (m, 12 H, CH3); 1.55 (s, 6H, CH3)
2.2.2. YP Loading of Terpenes (YP Terpene)
Dry YPs were mixed with 0.5 µL water per mg YP. Then, terpene was absorbed into
YPs by adding 1 mg terpene per mg YP and incubated at room temperature for 18–24 h for
samples containing carvacrol, geraniol or eugenol, and at 65 ◦C for 18–24 h for samples
containing thymol.
2.2.3. YP Loading of Pro-Terpenes (YP Pro-Terpene)
Dry YPs were mixed with 0.5 µL water per mg YP. Then, pro-terpene was absorbed
into YPs by swelling the particles with a solution of pro-terpene in DMSO (2.5 µL/mg
YP). The samples were incubated at room temperature for 18–24 h to complete the loading.
The YP pro-terpene was then lyophilized, and the loading process was repeated until the
target concentration of encapsulated pro-terpene was achieved. YP pro-terpene samples
contained 1.78–1.85 mg pro-terpene per mg YP to yield 1 mg terpene/mg YP upon pro-
terpene hydrolysis.
2.2.4. Characterization of Terpene and Pro-Terpene Loading Efficiency
Samples were stained with Nile red to qualitatively assess loading by the fluorescence
microscopy of the encapsulated terpene or pro-terpene Nile red complex. YP terpene and
YP pro-terpene samples were suspended in water at a concentration of 10 mg YP/mL.
The samples were centrifuged to collect excess liquid (free terpene or pro-terpene). The
supernatants and YP pellets were incubated in 0.1 M sodium carbonate buffer (pH 10) for
3 h to hydrolyze pro-terpene and then the samples were diluted with methanol to quantify
free (supernatant fraction) and YP encapsulated (pellet fraction) terpene. Terpenes were
quantified by HPLC [22] operated with 32 KaratTM software version 7.0 (Beckman Coulter,
Inc, Brea, CA, USA), using a Waters Symmetry® C18 column (3.5 µm, 4.6 × 150 mm) with
acetonitrile:water 70:30 as mobile phase, flow rate at 1 mL/min, injection volume of 10 µL,
and terpene detection at 254 nm. This isocratic HPLC method allows for the detection of
single terpene samples with the following retention times: 3.35 min (carvacrol), 2.73 min
(eugenol), 3.35 min (geraniol), and 3.42 min (thymol). The quantification of terpenes was
done by measuring the peak area and interpolating the concentration using a calibration
curve obtained with terpene standards.
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2.2.5. Terpene Release from YPs
YP terpene and YP pro-terpene samples were suspended in phosphate buffer saline
(PBS, pH 7) at a concentration of 1 mg YP/mL (=1 mg terpene/mL) and incubated at
37 ◦C. Aliquots were collected at predetermined times, centrifuged and the supernatant
was collected to quantify terpene released from the particles by HPLC.
2.2.6. Antimicrobial Activity Assays in Model Bacterial and Fungal Organisms
The antimicrobial activity of YP terpene and YP pro-terpene was evaluated using
a modified microplate assay published procedure [25]. Samples of YP terpene and YP
pro-terpene were suspended in 100 µL of growth medium (LB was used in antibacterial
assays and YPD in antifungal assays) and added to the first row (Row A) of a 96-well plate
(all wells in the 96-well plate contain additional 100 µL medium). Serial dilution (1:1) was
performed by transferring 100 µL from Row A to Row B, etc., and finally removing 100 µL
from Row H. Diluted Escherichia coli Top10 (Invitrogen, Carlsbad CA) or Saccharomyces
cerevisae Cry1 [26] cells (100 µL, 106 cells/mL) were added to all wells of the plate. Initial
(t = 0) and final (t = 16 h, 37 ◦C) absorbance readings were taken at 650 nm. The minimum
inhibitory concentration (MIC) was determined as the concentration that inhibits bacterial
or fungal growth by more than 75%.
2.2.7. Antimicrobial Assay with Fractionated Samples
YP pro-carvacrol samples (10 mg carvacrol/mL) were incubated 18 h at 37 ◦C in fresh
LB and LB collected from E. coli culture (spent LB). The samples were centrifuged to collect
the supernatant and YP pellet fractions; an aliquot of the supernatant was used to quantify
released carvacrol by HPLC. The pellet fractions were suspended in water and an aliquot
was used for HPLC analysis. Both supernatant and pellet fractions used for HPLC analysis
were incubated in 0.1 M carbonate buffer (pH 10) for 3 h to hydrolyze pro-terpene and
then diluted with methanol (final composition of 90% methanol) to solubilize terpene.
The remaining supernatant and pellet samples were evaluated for antibacterial activity on
E. coli, as described above.
2.2.8. Simulated Digestion Assay
YP terpene and YP pro-terpene samples were suspended in simulated gastric fluid
(SGF) [27] containing 3.2 mg pepsin/mL at a concentration of 1 mg terpene/mL. The
samples were incubated for 1 h at 37 ◦C, centrifuged and the SGF supernatant was col-
lected. The pellet was suspended in simulated intestinal fluid (SIF) [28] containing 10 mg
pancreatin/mL, incubated at 37 ◦C for 1 h, and centrifuged to collect SIF supernatant. The
pellet was suspended again in SIF with fresh pancreatin, and incubated at 37 ◦C for 1 h.
Terpene released from YPs was quantified in all supernatants by HPLC.
2.2.9. Nematode Extract Assay
Ascaris suum 4th stage larvae (350 mg) were isolated from pig intestines between
14–21 days after inoculation [29] and were immersed in PBS (pH 7) or 0.1 M sodium acetate
buffer (pH 5) and sonicated with a microtip sonicator probe at maximum power multiple
times for 30 s until the worm was disintegrated. Samples were kept on ice during sonication.
Total protein in worm extracts was quantified using the bicinchoninic acid protein assay
kit (ThermoFisher Scientific, Waltham, MA, USA) with bovine serum albumin control
(10.3 ± 1.7 mg protein/mL in worm extract pH 7, 9.2 ± 0.5 mg protein/mL in worm extract
pH 5). YP pro-carvacrol samples were suspended in worm extract at a target carvacrol
concentration of 20 mg/mL for 24 h at 37 ◦C. Control YP pro-carvacrol samples were
incubated in PBS, acetate buffer, and 0.1 M carbonate buffer pH 10. Samples were diluted
1:1 with methanol, centrifuged, the supernatant was collected and the released carvacrol
was quantified by HPLC. Supernatants and YP pro-carvacrol pellets were evaluated for
antimicrobial activity on E. coli.
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2.2.10. Larval Development (Egg-to-Larvae (E2L)) Assay
An E2L assay was used to measure the effects of carvacrol and pro-carvacrol on the de-
velopment of cyathostomin larvae from eggs to third-stage larvae (L3) [30]. Cyathostomin
eggs were collected from the feces of an equine herd [31]. Approximately 60 nematode eggs
were added to each well of a 96-well plate using a repeat dispensing pipette. YP samples
(10 µL of each working solution) were impregnated into 90 µL of S medium with E. coli
OP50. Control wells received 10 µL of water only. The plates were incubated for 7 days
at 28 ◦C, larvae were then killed using Lugol’s iodine, and the number of fully grown
infective L3 were counted in each well. Each concentration-response experiment consisted
of triplicate wells.
2.2.11. Adult Worm In Vitro Screening
Ancylostoma ceylanicum worms were maintained in golden Syrian hamsters, as previ-
ously described [32]. Trichuris muris parasites were maintained in STAT6-/-mice [33]. Adult
worms were harvested from infected rodents and washed using prewarmed medium (RPMI
1640 with 25 mM HEPES (pH 7.2) and antimicrobials (100 U/mL penicillin, 100 µg/mL
streptomycin, fungizone (10 µg/mL for A. ceylanicum, 2.5 µg/mL for T. muris)). Worms
were manually picked into the wells of the 48-well screening plate (1 worm per well) con-
taining 250 µL RPMI per well. As serum is incompatible with the assays with YP-terpenes,
it was left out. YP terpene and YP pro-terpene samples were evaluated at a concentration
of 333 µg terpene/mL [22]. Assay plates were incubated at 37 ◦C and 5% CO2. Terpene
activity was determined by motility of adult worms measured with an in-house assem-
bled Worminator [34]. The Worminator consists of a dark field illuminator, plate holder
and video camera placed under the assay plate. Worm motility was recorded using the
“WormAssay” software [34], measuring the average motility in each well based on pixel
displacement between frames over a given time. Data is expressed as mean motility units
and percent inhibition of motility was calculated relative to the mean motility units of
control worms (worms incubated with media).
3. Results
3.1. Preparation and Characterization of Yeast Particle Encapsulated Terpenes and Pro-Terpenes
3.1.1. Synthesis of Pro-Terpenes
To improve the stability of YP-terpenes and to better control sustained terpene release,
we designed pro-terpene compounds with the following properties: (1) solid at room
temperature to prevent terpene loss due to high volatility of terpene compounds, (2) water
insoluble to avoid premature terpene release and loss in diluted samples, (3) stable at
neutral pH, and (4) susceptible to chemical or enzymatic hydrolysis of a biodegradable
linker providing for controlled terpene release.
Pro-terpenes were synthesized via ring-opening transesterification of EDTA dianhy-
dride with the hydroxyl group of terpenes (carvacrol, eugenol, thymol, and geraniol) in
the presence of triethylamine (TEA) to yield diacids of terpenes with ester biodegradable
bonds, as depicted in Figure 1. The pro-terpenes have high melting points compared to
terpenes (three of the terpenes are liquid at room temperature) and are practically insoluble
in water (Table 1). The high melting point, poor water solubility, and biodegradable linkers
make these pro-terpenes suitable candidates for the development of stable YP pro-terpene
formulations with controlled terpene release.
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Pro-thymol 2 135–138 Insoluble 
Geraniol 1 −15 0.1 mg/mL 
Pro-geraniol 2 Decomposes above 145 Insoluble 
1 Terpene data from PubChem [35]. 2 Pro-terpene data determined experimentally 
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Figure 1. Synthesis of pro-terpenes.
Table 1. Melting point and solubility in water of terpenes and pro-terpenes.
Compound Melting Point (◦C) Solubility in Water
Carvacrol 1 3.5 1.25 mg/mL
Pro-carvacrol 2 156–158 Insoluble
Eugenol 1 −9.2 1.44 mg/mL
Pro-eugenol 2 167–169 <20 µg/mL
Thymol 1 51.5 0.90 mg/mL
Pro-thymol 2 135–138 Insoluble
Geraniol 1 −15 0.1 mg/mL
Pro-geraniol 2 Decomposes above 145 Insoluble
1 Terpene data fro PubChem [35]. 2 Pro-terpen data determined experimentally.
3.1.2. Yeast Particle E capsulation of Terpenes and Pro-Terpenes
YPs are 3–5 µm, holl w and porous microparticles derived from Baker’s yeast. The
porous cell wall structure makes these particles excellent absorbent materials, and payloads
can b loaded from aqueous and s me organic solutions with high payload loading capacity
and efficiency in the large hollow cavi y of the particles. Our first-ge eration terpene
encapsulation approach is depicted in Figure 2a and is based on the loading of terpenes
inside the hydrophobic cavity of YPs by the passive diffusi n of the payload through
the porous cell walls in an aqueous su pe sion of YPs. High t rpene loading (1:1 w/w
terpene:YP for materials reported in this publication and up to 3:1 w/w (unpublished
results)) is achieved with this method. Terpene release from YPs i based on passive
diffusion out of the particles and is a fu ction of terpene water s lubility with complete
terpene release in minutes to a few hours [22].
A second-generation approach was developed to better control terpene release from
YP encapsulated pro-terpenes (Figure 2b). The pro-terpenes are highly soluble in dimethyl-
sulfoxide (DMSO), a suitable solvent for payload loading in YPs that is removed by
lyophilization without loss of pro-terpene. Encapsulation of terpene and pro-terpenes
in YPs was assessed qualitatively by microscopy and quantitatively by HPLC. Nile red
dye was used to stain terpenes and pro-terpenes to visualize payload encapsulation, as
shown in Figure 2c for YP samples containing carvacrol. The HPLC results showed that
terpenes and pro-terpenes were encapsulated with >95% efficiency at a target loading ratio
of 1:1 terpene:YP or 1.85–1.90:1 pro-terpene:YP (to yield a 1:1 terpene:YP and 0.85–0.9:1
EDTA:YP ratio).
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3.1.3. Terpene Release fro YP Terpene and YP Pro-Terpene Sa ples
Terpene release fro YP terpene is based on passive diffusion out of the particles and
is a function of terpene water solubility. The four terpenes evaluated in this study have
similar water solubility (~1 mg/mL) and terpenes are rapidly released from YPs (e.g., >90%
carvacrol released at 1 h) upon dilution at concentrations equal or less than 1 mg/mL [22].
The pro-terpenes are water insoluble and their release from YPs is dependent on pH
or enzymatic hydrolysis of the ester bonds. We previously showed [23] that the kinetics
of pro-terpene hydrolysis is pH dependent with the ester bonds of the pro-terpenes being
susceptible to fast hydrolysis in basic pH (>50% pro-carvacrol hydrolyzed within 30 min at
pH 10) and increased stability at lower pH values (it took 4 days at pH 7, 21 days at pH 5,
and more than 2 months at pH 1.5 to reach 50% hydrolysis of pro-carvacrol) [23].
The YP terpene and YP pro-terpene compositions were evaluated for terpene release
in phosphate buffer saline (PBS, pH 7) at 37 ◦C. The results in Figure 3 clearly show that
YP pro-terpenes have greater pH 7 stability than YP terpenes. All YP terpene samples
rapidly released their payload in PBS upon dilution of the sample to 1 mg terpene/mL. YP
pro-terpenes resuspended in PBS at the same concentration showed a small burst release
(<20%), followed by slow hydrolysis and sustained terpene release over two weeks to
achieve complete control, and sustained terpene release from YPs.
Next, we evaluated YP terpenes and YP pro-terpenes samples for stability during
simulated digestion (Figure 4). Samples were first incubated in simulated gastric fluid
(SGF) containing pepsin, followed by incubation in simulated intestinal fluid (SIF) contain-
ing pancreatin.
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Terpenes are released from YP terpenes in SGF, primarily due to terpene diffusion out
of the particles. YP pro-terpenes are stable in SGF due the pro-terpenes water insolubility,
slow hydrolysis at pH < 2, and non-susceptibility to degradation by pepsin (pepsin is an
endopeptidase that breaks amide peptide bonds). Terpenes were partially released from
YP pro-terpenes in SIF due to the presence of lipases in pancreatin that hydrolyze ester
linkages. Pancreatin activity in simulated digestion is lost within 1 h. To demonstrate the
effect of enzyme activity on YP pro-terpene hydrolysis and release, samples were subjected
to two sequential 1 h incubations in fresh SIF + pancreatin.
3.2. Biological Activity of YP Pro-Terpenes
The biological activity of YP pro-terpenes was evaluated against different model
organisms to demonstrate that YP encapsulated pro-terpenes retain the broad-spectrum
anti-pathogen effects (antibacterial, antifungal, and anthelmintic) of free terpenes and
YP terpenes.
Antimicrobial activity of YP pro-terpenes: YP pro-terpene samples were tested for
antibacterial activity against E. coli. Table 2 shows the minimum inhibitory concentrations
(MICs) of YP samples and controls. Empty YPs have no antimicrobial effect on E. coli. For
the three terpenes evaluated on E. coli, the free terpene, YP terpene and YP pro-terpene
samples show similar antibacterial activity. Hydrolysis of pro-terpenes generates EDTA
as byproduct and a control sample of YP+EDTA containing the same amount of EDTA
generated from pro-terpene hydrolysis was evaluated to confirm that the antimicrobial
effect of YP pro-terpene samples was due to the terpene released from the particles and not
from the EDTA byproduct.
Table 2. In vitro antibacterial activity on E. coli of free terpene, YP terpene and YP pro-terpene samples.
Sample MIC 75% (Average of n = 4)
Negative controls
Empty YP Not active
YP + EDTA 4244 ± 1400 µg EDTA/mL
Carvacrol samples
Carvacrol 625 ± 0 µg carvacrol/mL
YP carvacrol 677 ± 45 µg carvacrol/mL
YP pro-carvacrol 625 ± 0 µg carvacrol/mL
Eugenol samples
Eugenol 938 ± 361 µg eugenol/mL
YP eugenol 312 ± 0 µg eugenol/mL
YP pro-eugenol 625 ± 442 µg eugenol/mL
Geraniol samples
Geraniol 1094 ± 313 µg geraniol/mL
YP geraniol 781 ± 312 µg geraniol/mL
YP pro-geraniol 1094 ± 312 µg geraniol/mL
The antibacterial effect against E. coli is due to bacterial absorption of terpene present
in the LB medium added as free terpene or terpene released from YP terpenes (all MICs are
below the maximum solubility of terpenes in water). The kinetics of pro-terpene hydrolysis
at neutral pH (pH of LB = 6.8) make it unlikely to achieve high enough terpene release
from YP pro-terpene samples during the 18 h incubation required for this experiment.
Additionally, the pro-terpenes are insoluble in LB medium and YPs are not internalized by
E. coli; therefore, it is not possible for pro-terpene hydrolysis to occur inside the bacteria.
We hypothesized that YP pro-terpenes are hydrolyzed by esterases secreted from E. coli into
the LB medium. Samples of YP pro-carvacrol were incubated for 18 h in fresh LB or in LB
bacterial cell-free spent media collected after E. coli culture (LB spent media). The samples
were centrifuged to collect the supernatant and YP pellet fractions; carvacrol generated
from pro-terpene hydrolysis was quantified in supernatants by HPLC, and the samples
were added to E. coli to evaluate the antibacterial activity of each fraction (Table 3). The YP
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pro-carvacrol samples incubated in fresh LB medium released <5% of carvacrol. Samples
incubated in spent media released 35 ± 6% carvacrol into the supernatant confirming that
pro-terpenes are hydrolyzed by enzymes secreted from E. coli into the LB medium. The
HPLC analysis of the pellet fractions showed that carvacrol retained in the pellet was in
the form of pro-carvacrol for both samples incubated in fresh or spent media. The HPLC
results were used to correct carvacrol concentration in supernatant and pellet fractions
added to E. coli. The results in Table 3 show that only the pellet fraction was active for the
sample incubated in fresh LB medium and both fractions collected from spent LB medium
were active.
Table 3. In vitro antibacterial activity on E. coli of YP pro-carvacrol sample before and after incubation
in LB spent media.
LB Fraction MIC 75% (µg Carvacrol/mL, Average of n = 3)
Fresh
Supernatant Not active
Pellet 521 ± 180
Spent
Supernatant 500 ± 216
Pellet 729 ± 252
Next, we evaluated YP pro-terpenes for antifungal activity against S. cerevisae. The
results in Table 4 show that empty YP and YP+EDTA are not active against S. cerevisae and
the three terpenes evaluated in this assay show similar MIC values for free terpene, YP
terpene, and YP pro-terpene samples. The activity of YP pro-terpene sample is likely due
to a similar effect shown with E. coli, with terpene release from YPs upon hydrolysis of
pro-terpene induced by esterases secreted by fungi.
Table 4. In vitro antifungal activity on Saccharomyces cerevisae of free terpene, YP terpene and YP
pro-terpene samples.
Sample MIC 75% (Average of n = 3)
Negative controls
Empty YP Not active
YP + EDTA Not active
Eugenol samples
Eugenol 703 ± 773 g eugenol/mL
YP eugenol 390 ± 193 µg eugenol/mL
YP pro-eugenol 781 ± 362 µg eugenol/mL
Thymol samples
Thymol 312 ± 110 µg thymol/mL
YP thymol 1250 ± 442 µg thymol/mL
YP pro-thymol 781 ± 312 µg thymol/mL
Geraniol samples
Geraniol 703 ± 773 µg geraniol/mL
YP geraniol 312 ± 221 µg geraniol/mL
YP pro-geraniol 260 ± 90 µg geraniol/mL
Anthelmintic activity of YP pro-terpenes: We recently reported the testing of 17 YP
terpenes as broad-acting anthelmintics [22]. YP terpenes or subsets of them were active
against hookworms (Ancylostoma ceylanicum and Nippostrongylus brasiliensis) and whip-
worm (Trichuris muria), and overcame albendazole-resistant Caenorhabditis elegans. YP
encapsulation provides an approach that could lead to the development of anthelmintic
terpene formulations for oral delivery. The new YP encapsulation approach using pro-
terpenes with stimuli-controlled terpene release could provide materials that overcome
fast terpene release and absorption in the stomach.
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First, we evaluated if YP pro-terpenes are susceptible to hydrolysis by enzymes in
a nematode (Ascaris suum) extract. YP pro-carvacrol samples were incubated in Ascaris
extract at pH 7 and pH 5. Control samples were incubated in buffer only including a control
in 0.1 M carbonate buffer (pH 10) for complete pro-carvacrol hydrolysis and carvacrol
release from YP. The samples were centrifuged to collect the supernatant and YP pellet
fractions, carvacrol was quantified in supernatants, and both fractions were evaluated for
antimicrobial activity on E. coli. The results in Table 5 show that YP pro-carvacrol was
susceptible to hydrolysis by esterases in the Ascaris extract with 5–6-fold higher carvacrol
release in the Ascaris extract compared to buffer controls. There was antimicrobial activity
from terpene present in both supernatant and pellet fractions of samples incubated in
Ascaris extract, but only the pellet fraction of samples incubated in pH 7 and pH 5 buffers
is active. The control sample in pH 10 buffer (no worm extract) showed the expected
complete carvacrol release and antibacterial activity only in the supernatant fraction.
Table 5. Hydrolysis of YP pro-carvacrol in Ascaris suum extract and antibacterial activity on the E. coli of the supernatant
containing carvacrol released from the YPs and YP pellet fraction containing residual encapsulated pro-carvacrol.
Buffer ± Ascaris Extract % Carvacrol Released from
YPs after 24 h Incubation
MIC 75%
(µg carvacrol/mL, Average of n = 3)
Supernatant Pellet
PBS (pH 7) 4.5 ± 1.8 Not active 597
Ascaris extract in PBS (pH 7) 27.9 ± 6.0 291 ± 101 451 ± 0
Acetate buffer (pH 5) 6.5 ± 0.9 325 584
Ascaris extract in acetate buffer (pH 5) 37.3 ± 9.5 155 ± 67 261 ± 113
Carbonate buffer (pH 10) 95.6 ± 1.2 598 Not active
Next, the biological activity of YP pro-terpenes and YP terpenes was assessed in three
in vitro nematode assays: (1) development of the horse parasite cyathostomin from egg to
third-stage larvae [30], (2) toxicity in adult hookworm (A. ceylanicum) and (3) toxicity in
adult whipworm (T. muris).
YP pro-carvacrol and YP carvacrol were evaluated in the cyathostomin E2L assay
with samples showing similar dose-response activity (Figure 5) completely inhibiting
E2L development at a concentration of 100 µg carvacrol/mL. A control of YP+EDTA also
had some toxicity (~40–45% inhibition of larvae development, data not shown) at the
highest EDTA concentration equivalent to the expected amount of EDTA generated from
the hydrolysis of YP pro-carvacrol at 100 µg/mL. The long incubation period (seven days)
required for the Cyathostomin E2L assay likely increased the impact of EDTA complexation
of metal ions critical in processes of larvae development.
YP pro-terpene and YP terpene samples were evaluated at a concentration of 333 µg
terpene/mL in the adult hookworm and whipworm assays. We previously identified all
four terpenes to have a fast-acting effect on hookworm at the selected terpene concentration
of 333 µg /mL [22]. We also demonstrated that hookworms readily ingest YPs which leads
to two possible mechanisms of terpene entry: (1) hookworm ingestion of terpene released
from YPs or (2) hookworm ingestion of YP terpene or YP pro-terpene and subsequent
terpene release inside the worms. The results in Figure 6 show that all samples were active
against hookworm after 2-h and 24 h incubation and YP+EDTA control was non-toxic.
Foods 2021, 10, 1207 12 of 15




Figure 5. In vitro activity of carvacrol samples in cyathostomin egg-to-larvae (E2L) assay. 
YP pro-terpene and YP terpene samples were evaluated at a concentration of 333 µg 
terpene/mL in the adult hookworm and whipworm assays. We previously identified all 
four terpenes to have a fast-acting effect on hookworm at the selected terpene concentra-
tion of 333 µg /mL [22]. We also demonstrated that hookworms readily ingest YPs which 
leads to two possible mechanisms of terpene entry: (1) hookworm ingestion of terpene 
released from YPs or (2) hookworm ingestion of YP terpene or YP pro-terpene and subse-
quent terpene release inside the worms. The results in Figure 6 show that all samples were 
active against hookworm after 2-h and 24 h incubation and YP+EDTA control was non-
toxic. 
YP pro-carvacrol and YP carvacrol samples were evaluated for in vitro activity in the 
whipworm assay at a concentration of 333 µg/mL. Unlike hookworms, whipworms do not 
ingest YPs and therefore toxicity of YP terpenes in whipworm only occurs due to whip-
worm absorption of terpene released from YPs into the whipworm assay media [22]. The 
results in Figure 6 show >70% inhibition of whipworm motility after 2 h incubation with 
YP carvacrol due to fast release of carvacrol from YP carvacrol, but the YP pro-carvacrol 
sample is less active after 2 h incubation. This reduced activity after 2-h is expected as 
carvacrol release from YP pro-carvacrol requires hydrolysis of pro-carvacrol mediated by 
esterases secreted by whipworm into the media, followed by carvacrol diffusion from YPs. 
Both YP carvacrol and YP pro-carvacrol showed similar inhibition of whipworm motility 
































Figure 5. In vitro activity of carvacrol samples in cyathostomin egg-to-larvae (E2L) assay.




Figure 6. Inhibition of adult hookworm and whipworm motility by YP terpenes and YP pro-ter-
penes after 2 and 24 h incubation (results are average of eight worms per treatment). Percent inhi-
bition of motility was calculated relative to the mean motility units of control worms (no treat-
ment). 
4. Discussion 
Terpenes are natural products of great commercial interest due to their wide array of 
functional properties. Microencapsulation of terpenes in some products is challenging 
due to their high volatility and susceptibility to degradation. We previously developed 
methods to use yeast particles for the encapsulation of terpenes without the need for al-
cohols or surfactants. These YP terpenes have been shown to exhibit broad anthelmintic 
activity [22] and two YP terpene-based products have been developed and commercial-
ized as a fungicide and nematicide for agricultural applications [16–21]. The goals of de-
veloping a second generation of YP terpene materials were to improve terpene encapsu-
lation stability and to provide for stimuli-responsive controlled terpene release. This new 
approach employs pro-terpene compounds that are (1) solid at room temperature to avoid 
loss due to the high volatility of terpenes, (2) water-insoluble to prevent premature release 
from YPs, (3) stable at neutral pH, and (4) contain a stimuli-controlled (pH, enzyme) bio-
degradable bond for controlled terpene release. 
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YP pro-carvacrol and YP carvacrol samples were evaluated for in vitro activity in
the whipworm assay at a concentration of 333 µg/mL. Unlike hookworms, whipworms
do not ingest YPs and therefore toxicity of YP terpenes in whipworm only occurs due to
whipworm absorption of terpene released from YPs into the whipworm assay media [22].
The results in Figure 6 show >70% inhibition of whipworm motility after 2 h incubation with
YP carvacrol due to fast release of carvacrol from YP carvacrol, but the YP pro-carvacrol
sample is less active after 2 h incubation. This reduced activity after 2-h is expected as
carvacrol release from YP pro-carvacrol requires hydrolysis of pro-carvacrol mediated by
esterases secreted by whipworm into the media, followed by carvacrol diffusion from YPs.
Both YP carvacrol and YP pro-carvacrol showed similar inhibition of whipworm motility
after 24 h incubation.
4. Discussion
Terpenes are natural products of great commercial interest due to their wide array
of functional properties. Microencapsulation of terpenes in some products is challenging
due to their high volatility and susceptibility to degradation. We previously developed
methods to use yeast particles for the encapsulation of terpenes without the need for
alcohols or surfactants. These YP terpenes have been shown to exhibit broad anthelmintic
activity [22] and two YP terpene-based products have been developed and commercialized
as a fungicide and nematicide for agricultural applications [16–21]. The goals of developing
a second generation of YP terpene materials were to improve terpene encapsulation stability
and to provide for stimuli-responsive controlled terpene release. This new approach
employs pro-terpene compounds that are (1) solid at room temperature to avoid loss due
to the high volatility of terpenes, (2) water-insoluble to prevent premature release from YPs,
(3) stable at neutral pH, and (4) contain a stimuli-controlled (pH, enzyme) biodegradable
bond for controlled terpene release.
High encapsulation efficiency (>95%) of both pro-terpenes or terpenes in YPs was
achieved at a target terpene:YP weight ratio of 1:1. Terpene release from YP terpenes
is dependent on the diffusion of terpene from the particles and is a function of terpene
solubility with complete release in minutes to a few hours upon dilution of YP terpene
below its maximum solubility in water. Terpene release from YP pro-terpenes is a function
of pro-terpene hydrolysis in response to an external stimulus, followed by terpene diffusion
from YPs. Terpene encapsulation stability is improved using pro-terpenes, extending the
release of terpene at pH 7 from a few hours (YP terpene) up to two weeks (YP pro-terpenes).
The YP pro-terpene and YP terpene samples showed similar biological activity in
antibacterial, antifungal and anthelmintic in vitro assays. The activity of YP pro-terpene in
these assays is mediated by the presence of esterases to induce hydrolysis of the pro-terpene
and subsequent terpene release from YPs. The enhanced stability and controlled release of
YP pro-terpenes could allow for developing terpene formulations for applications such as
(1) environmental biocontrol agent applied directly to contaminated soil or a pass through
in feed to reduce transmission of gastrointestinal parasitic nematodes by targeting develop-
ing/infectious larvae of parasites that infect livestock and humans in the third larval stage
(e.g., cyathostomins, Haemonchus, Ostertagia, hookworms), (2) formulations for oral delivery
of terpenes for targeting of internal gastrointestinal parasites, and (3) controlled-release
of terpenes as food fragances and flavors, or as antimicrobial agents in food preservation.
Future work will focus on the in vivo evaluation of YP pro-terpenes.
This new approach of payload encapsulation in YPs using pro-terpenes can be ex-
panded to a broad range of small drug molecules that are difficult to trap using previously
developed yeast particle drug encapsulation methods. We are currently investigating this
approach to stably generate encapsulated yeast particle pro-drugs with stimuli-controlled
drug release for a broad range of payload molecules such as antibacterials (e.g., isoniazid,
oxazolidinones, and cycloserine), anti-inflammatories (e.g., naproxen, ibuprofen), and
chemotherapeutics (e.g., doxorubicin).
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5. Conclusions
Yeast particles can be used for the encapsulation of scaffolded terpene compounds
containing a biodegradable linker to control terpene release. These YP pro-terpene samples
exhibit the same loading capacity as YP terpenes, and with additional benefits of improved
stability and control over terpene release in response to pH or esterase induced hydrolysis
of the pro-terpene compound. Both YP terpenes and YP pro-terpenes exhibit biological
activity in antimicrobial and anthelmintic assays.
6. Patents
Yeast Cell Wall Particle Encapsulation of Biodegradable Pro-Payloads. G.R. Ostroff
and E. R. Soto. US Patent App. 16/981,072, 2021. 28 January 2021.
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